Boston Scientific reported net sales of $3.127 billion for Q4 2021, a 15.4% increase year-over-year. GAAP net income available to common stockholders was $80 million, or $0.06 per share, while adjusted EPS reached $0.45. The company's performance was driven by growth across all reportable segments and regions.
Net sales increased by 15.4% on a reported basis, reaching $3.127 billion.
GAAP net income available to common stockholders was $0.06 per share.
Adjusted EPS reached $0.45 per share.
The company achieved net sales growth in each reportable segment.
The company estimates net sales growth for the full year 2022 to be in the range of approximately 6 to 8 percent on both a reported basis and organic basis. The company estimates EPS on a GAAP basis in a range of $0.94 to $1.04 and adjusted EPS, excluding certain charges (credits) of $1.73 to $1.79.
Visualization of income flow from segment revenue to net income